Related Experiment Videos
Cellular and plasma adriamycin concentrations in long-term infusion therapy of leukemia patients
P A Speth1, P C Linssen, J B Boezeman
1Department of Hematology, St. Radboud University Hospital, Nijmegen, The Netherlands.
Abstract:
To determine whether long-term adriamycin (ADM) infusions resulted in cellular ADM concentrations at least comparable to those observed after bolus injections, ADM cellular and plasma concentrations were measured in 18 patients with leukemia. ADM was administered at 30 mg/m2 per day for 3 days, either as bolus injections or as 4-, 8-, or 72-h infusions. Negligible accumulation of plasma ADM was observed. Peak plasma ADM concentrations after bolus injections were 1640 +/- 470 ng/ml (n = 7). Maximum levels were 176 +/- 34 ng/ml during 4-h infusion (n = 5); 85 +/- 50 ng/ml during 8-h infusion (n = 4); and 47 +/- 5 ng/ml (n = 2) after 72-h infusion. ADM concentrations in nucleated blood and bone marrow cells correlated well (r = 0.82, n = 47). ADM accumulated in leukemic cells up to 30-100 times the plasma concentrations. The shorter the administration time-span, the higher the peak leukemic cell concentration and the greater the loss of drug immediately after the end of the administration. The final cellular ADM half-life was approximately 85-110 h. After long-term infusion and bolus injection of the same dose, similar areas under the curve for plasma or leukemic blast cell ADM concentrations were attained. Since comparable therapeutic efficacy was observed in all regimens, the antileukemic effect appeared not to be related to the peak plasma concentrations, while acute toxicity phenomena decreased with increasing duration of the infusion. Long-term ADM infusion deserves more attention in the treatment of patients with anthracyclines.
Insights
Long-term adriamycin (ADM) infusions achieve similar cellular concentrations as bolus injections, with reduced toxicity. This suggests prolonged ADM infusion warrants further investigation for leukemia treatment.
Area of Science:
- Oncology
- Pharmacology
- Hematology
Background:
- Adriamycin (ADM) is a key anthracycline chemotherapy agent.
- Understanding ADM pharmacokinetics is crucial for optimizing leukemia treatment.
- Cellular drug concentrations may better reflect efficacy than plasma levels.
Purpose of the Study:
- To compare cellular and plasma adriamycin concentrations after bolus injection versus prolonged infusions.
- To evaluate the relationship between ADM administration method, cellular drug levels, and toxicity.
- To assess the therapeutic implications of different ADM administration strategies in leukemia.
Main Methods:
- 18 leukemia patients received ADM (30 mg/m²/day for 3 days) via bolus or 4-, 8-, or 72-h infusions.
- Plasma and cellular (blood/bone marrow) ADM concentrations were measured.
- Correlation between cellular and plasma levels, and drug half-life were analyzed.
Main Results:
- Cellular ADM concentrations were 30-100 times higher than plasma levels.
- Longer infusion durations resulted in lower peak plasma concentrations but comparable overall cellular exposure.
- Similar therapeutic efficacy was observed across regimens, with decreased acute toxicity for longer infusions.
Conclusions:
- Long-term adriamycin infusion can achieve comparable leukemic cell drug levels to bolus injections.
- Antileukemic effect is not solely dependent on peak plasma concentrations.
- Prolonged ADM infusion may offer a better toxicity profile and warrants further clinical consideration.